首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

1425118

光化性角化症治療市場－2024年至2029年預測

Actinic Keratosis Treatment Market - Forecasts from 2024 to 2029

出版日期: 2024年01月24日 | 出版商:

Knowledge Sourcing Intelligence | 英文 140 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

2022年光化性角化症治療市場規模為82.51億美元。

稱為光化性角化症的癌前皮膚病變需要個別化護理，這可能導致治療依從性差和結果不佳。關於個人化護理的資訊很少，特別是根據患者偏好和目標量身定做治療以及促進患者和醫療保健提供者之間的共用決策。

皮膚癌盛行率增加

根據疾病管制與預防美國，最常見的癌症是皮膚癌。有關默克爾細胞癌和其他非上皮皮膚惡性的資料由中央癌症登記處收集。最常見的皮膚癌類型、基底細胞癌和鱗狀細胞癌，中央癌症登記處收集的頻率較低。根據醫療支出小組調查統計，每年有超過610萬人接受基底細胞癌和鱗狀細胞癌治療，費用約89億美元。因此，光化性角化症的病例正在增加。

治療中的個人化光化性角化症治療

在治療慢性皮膚病時，患者對長期重複治療方法的依從性對於治療效果至關重要，這推動了光化性角化病治療產業的發展。醫療保健提供者 (HCP) 可以從診斷的角度與患者合作，了解他們獨特的目標、擔憂和治療期望，從而提供個人化護理。患者和 HCP 之間持續的共用決策可以提高依從性並最佳化治療結果。

光化性角化症的治療

AK 的治療方法具有不同的功效和安全性，這推動了光化性角化症治療市場的發展。治療方法：「病變定向」（即治療同一區域內的單一或極少數 AK 病變）和「病變定向」（即治療臨床上明顯的病變且無病變）。作為一個針對整個周圍區域有明顯變化的區域）。治療方法的選擇通常是個別化的，並且始終取決於患者和病變的特徵，尤其是老年人。這類 AK 患者經常有高血壓、心血管疾病、糖尿病和神經功能障礙等合併症，在選擇特定藥物和確定患者堅持治療的傾向時應考慮這些合併症。

雷射治療日益普及

單一 AK 病灶和 FC 可以透過雷射治療去除光損傷的表皮和真皮乳頭或進行全臉部皮膚表面定序。據報道，在 AK 治療中，使用二氧化碳和摻鉺釔鋁石榴石進行完全定序雷射換膚作為單一療法比部分燒蝕技術更有效，儘管癒合時間較長。根據國家醫學圖書館的資料，雷射換膚單一療法與 5-FU 和 30% TCA 一樣有效，但不如 PDT 有效。平均而言，90% 的患者對治療有反應，10-15% 的患者在 6 個月內復發。

在北美，光化性角化病治療市場預計將穩定成長。

北美光化性角化病治療市場預計將受到該地區光化性角化病患病率不斷增加和研究措施的推動。專門從事醫學皮膚病學的國際生物製藥公司 Almirall SA (ALM) 進行的一項民意調查顯示，85% 的參與者對光化性角化病 (AK) 一無所知。鱗狀細胞癌 (SCC) 是第二常見的皮膚癌類型，可能是這種持續性皮膚病的結果。這項民意調查由 Almirall 對超過 2,500 名 35 歲及以上的人進行，旨在確定西班牙、德國、義大利、英國和美國公眾對 AK 和皮膚健康的認知。

FDA核准光化性角化症治療並進行臨床試驗

2023 年 1 月，全球生物製藥公司 Biofrontera AG 評估了 Amerous(R) 作為四肢、頸部和身體軀幹光化性角化病(AK) 定點治療的安全性和有效性。一項隨機、雙盲、安慰劑對照研究，多中心、3期臨床試驗已開始招募病患。
Almirall, SA 表示，2020 年 12 月，美國食品藥物管理局(FDA)核准Klisyri®（tirbanibulin）用於局部治療臉部或頭皮的光化性角化病(AK)。Almirall 是一家專門從事皮膚健康的全球生物製藥公司。 Crysiri®（通用名：tilvanibrin）預計將於 2021 年第一季在美國上市。

Precancerous skin lesions called actinic keratoses require individualized care, which can lead to poor treatment adherence and subpar results. There is little information on personalizing care, especially when it comes to adjusting therapy to each patient's preferences and goals and promoting shared decision-making between patients and healthcare providers.

Growing prevalence of skin cancer

As per the Centers for Disease Control and Prevention, the most prevalent type of cancer is skin cancer. Data on Merkel cell carcinoma and other non-epithelial skin malignancies are gathered by central cancer registries. The most prevalent kinds of skin cancer, basal cell, and squamous cell carcinomas, do not often have information gathered by central cancer registries. According to statistics from the Medical Expenditure Panel Survey, over 6.1 million individuals receive treatment for basal cell and squamous cell carcinomas annually, at a cost of about $8.9 billion. This leads to growing cases of actinic keratosis.

Personalization in treatment actinic keratosis treatment

When treating chronic skin disorders, patients' compliance with lengthy, repeated treatment regimens is crucial to the efficacy of the treatment which is boosting the actinic keratosis treatment industry. Healthcare providers (HCPs) can collaborate with their patients from the moment of diagnosis to understand their unique objectives, concerns, and treatment expectations to provide individualized care. Maintaining continuous, shared decision-making between patients and HCPs can enhance adherence and optimize treatment results to ultimately improve patient satisfaction and QoL, given the life-long nature of AK and the necessity for recurrent treatment sessions.

Management of Actinic Keratosis

For the management of AK, several therapies with various effectiveness and safety profiles are made available which is fueling the actinic keratosis treatment market. Therapies are categorized as "lesion directed" (i.e., treatments are conducted on a single or very small number of AK lesions within the same location) or "field directed," which targets the FC, i.e., the clinically evident lesions and the entire surrounding area with subclinical alterations. The choice of therapy is often made on an individual basis and is always dependent on the traits of both the patient and the lesion, especially in senior individuals. When selecting a specific medication and determining the patient's propensity to adhere to treatment, comorbidities including hypertension, cardiovascular disease, diabetes, and neurological dysfunctions are frequently present in this group of AK patients.

Growing popularity of laser therapies

Single AK lesions and FC can be treated with laser therapy, which can remove the actinic-damaged epidermis and papillary dermis or cause a full-face skin resurfacing. Fully ablative laser resurfacing using carbon dioxide and erbium-doped yttrium aluminium garnet has been reported to be more efficient as monotherapy than fractional ablative methods for treating AK, despite lengthy healing durations. Data from the National Library of Medicine indicate that laser resurfacing monotherapy is equally effective as 5-FU and 30% TCA and less effective than PDT, even though larger sample numbers for clinical studies are required. 90% of patients respond to therapy on average, and 10-15% relapse within 6 months.

In North America, it is projected that the actinic keratosis treatment market will grow steadily.

The actinic keratosis treatment market in North America is anticipated to be fueled by the growing prevalence of actinic keratosis and research initiatives in the region. A poll conducted by the international biopharmaceutical firm Almirall S.A. (ALM), which specializes in medical dermatology, revealed that 85% of participants were ignorant of actinic keratosis (AK). Squamous cell carcinoma (SCC), the second most typical kind of skin cancer, can develop as a result of this persistent skin disorder. The poll, performed by Almirall with more than 2,500 participants over the age of 35, sought to ascertain the general public's degree of awareness of AK and skin-healthy practices in Spain, Germany, Italy, the United Kingdom, and the United States.

Actinic Keratosis Treatment Procedures

Freezing (Cryotherapy), Liquid nitrogen freezing can be used to eliminate actinic keratoses. The material is applied to the damaged skin by healthcare professionals, which results in blistering or peeling. The injured skin cells peel off as the skin heals, revealing fresh skin. The most frequent kind of treatment is cryotherapy.
Scrapping (Curettage), The injured cells are scraped out during this treatment using a tool called a curet. Electrosurgery, which uses a pencil-shaped device to cut and vaporize the afflicted tissue with an electric current, may be performed after scraping.
Photodynamic Therapy, The doctor may apply a chemical solution that is light-sensitive to the damaged skin before exposing it to a specific light to eradicate the actinic keratosis. Skin inflammation, swelling, and a burning feeling may be side effects of treatment.

FDA Approvals and Clinical Trials for Actinic Keratosis Drugs

In January 2023, a randomized, double-blind, placebo-controlled, multi-center Phase 3 clinical trial to assess the safety and effectiveness of Ameluz® in a field-directed treatment of actinic keratosis (AK) on the extremities, neck, and trunk began enrolling patients, according to Biofrontera AG, a global biopharmaceutical company.
In December 2020, The U.S. Food and Drug Administration (FDA) authorized Klisyri® (tirbanibulin) for the topical treatment of actinic keratosis (AK) of the face or scalp, according to Almirall, S.A., a worldwide biopharmaceutical business specializing in skin health. During the first quarter of 2021, Klisyri® (tirbanibulin) will be made available in the United States.

Market Key Developments

In December 2022, Ameluz® and BF-RhodoLED® are being sold in Finland owing to Biofrontera AG (ISIN: DE0006046113), a global biopharmaceutical firm, and its Scandinavian licensing partner Galenica AB, Malmo, Sweden.
In September 2021, the commercial launch of Klisyri® (tirbanibulin), which was approved by the European Commission and the UK Medicines & Healthcare products Regulatory Agency (MHRA) in July and August of 2021, respectively, for the topical treatment of actinic keratosis (AK) of the face and scalp in adults, was announced by Almirall S.A., a global biopharmaceutical company.

Segmentation:

By Therapy

Photodynamic Therapy
Surgery
Topical Medications

By Drug Class

NSAIDs
Nucleoside Metabolic Inhibitor
Immune Response Modifiers
Photoenhancers

By End-User

Hospitals and Oncology Centers
Dermatology Clinics
Homecare
Others

By Geography

North America
United States
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
United Kingdom
Germany
France
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Israel
Others
Asia Pacific
Japan
China
India
South Korea
Indonesia
Thailand
Others

1. INTRODUCTION

1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

2.1. Research Data
2.2. Assumptions

3. EXECUTIVE SUMMARY

3.1. Research Highlights

4. MARKET DYNAMICS

4.1. Market Drivers
4.2. Market Restraints
4.3. Porter's Five Force Analysis
- 4.3.1. Bargaining Power of Suppliers
- 4.3.2. Bargaining Power of Buyers
- 4.3.3. Threat of New Entrants
- 4.3.4. Threat of Substitutes
- 4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis

5. ACTINIC KERATOSIS TREATMENT MARKET, BY THERAPY

5.1. Introduction
5.2. Photodynamic Therapy
5.3. Surgery
5.4. Topical Medications

6. ACTINIC KERATOSIS TREATMENT MARKET, BY DRUG CLASS

6.1. Introduction
6.2. NSAIDs
6.3. Nucleoside Metabolic Inhibitor
6.4. Immune Response Modifiers
6.5. Photoenhancers

7. ACTINIC KERATOSIS TREATMENT MARKET, BY END-USER

7.1. Introduction
7.2. Hospitals and Oncology Centers
7.3. Dermatology Clinics
7.4. Homecare
7.5. Others

8. ACTINIC KERATOSIS TREATMENT MARKET, BY GEOGRAPHY

8.1. Introduction
8.2. North America
- 8.2.1. United States
- 8.2.2. Canada
- 8.2.3. Mexico
8.3. South America
- 8.3.1. Brazil
- 8.3.2. Argentina
- 8.3.3. Others
8.4. Europe
- 8.4.1. United Kingdom
- 8.4.2. Germany
- 8.4.3. France
- 8.4.4. Spain
- 8.4.5. Others
8.5. The Middle East and Africa
- 8.5.1. Saudi Arabia
- 8.5.2. UAE
- 8.5.3. Israel
- 8.5.4. Others
8.6. Asia Pacific
- 8.6.1. Japan
- 8.6.2. China
- 8.6.3. India
- 8.6.4. South Korea
- 8.6.5. Indonesia
- 8.6.6. Thailand
- 8.6.7. Others